6 results
The objectives of this open-label study are to evaluate the efficacy (GL-3 clearance), pharmacokinetics (PK), and safety parameters (including immunogenicity) for 2 alternative dose regimens of Fabrazyme (0.5 mg/kg every 2 weeks [q2w] and 1.0 mg/kg…
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.
The purpose of this study was to demonstrate that the PP can be improved in chronic stroke survivors using a newly developed, intensive training. The effect of the new training on the PP, walking velocity and mobility at home will be determined.…
Primary objective:1) Does individually tailored robotic gait training with the LOPES II result in more reduction of mechanical work during walking and more improvement of gait symmetry than conventional gait training (of similar frequency and…
Primary objective:To evaluate the single- and multiple-dose safety and pharmacokinetics of CNM-Au8 upon oral administration of CNM-Au8 to healthy adult male and female subjects.Secondary objective:Exploreing the immune-modulating effects of CNM-Au8…